Adlai Nortye Ltd.

About Adlai Nortye Ltd.

Adlai Nortye (NASDAQ: ANL) is a global clinical-stage company focused on developing innovative targeted and immune-modulating cancer therapies. With R&D centers in the U.S. and China, their mission is to transform deadly cancer into a chronic and eventually curable disease.

Products & Services

AN8025:A trifunctional fusion protein (αPD-L1/Lag3v/CD86v) acting as a T cell and antigen-presenting cell modulator, currently at IND-enabling stage.

AN9025:An oral small molecule pan-RAS(ON) inhibitor, currently at IND-enabling stage.

Specialties

Targeted cancer therapies Immune-modulating therapies Immuno-oncology platforms

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: IPO T: - FT: IPO	A: 97500000 MR: - FA: US$97.5 million FAN: 97500000	D: 2023-09-29 FD: 2023-09-29	1 investors

IPO Latest

2023-09-29

$97.5M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Ronald M. Evans

SAB Chair

T

Tony Hunter

PhD

J

Jason Pontin

Investor

A

Andrew Zhu

MD, PhD

W

Wenle Xia

MD

Y

Yang (Carsten) Lu

CEO, Chairman of the Board of Directors

View 15 more team members with Pro

Unlock Full Team Directory

Recent News

Adlai Nortye Ltd. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised